Immunohistochemical Expression Pattern of Brac 1 and Progesterone Receptors among Female Breast Cancer Patient in Bayelsa State

Eric E. U. *

Department of Medical laboratory Science, Histopathology Unit, Niger Delta University, Bayelsa State. Nigeria.

Abraham K. D.

Department of Medical Laboratory Science, Microbiology/Molecular Unit, Niger Delta University, Bayelsa State, Nigeria.

*Author to whom correspondence should be addressed.


Abstract

Breast cancer is a diverse disease that exhibits a variety of clinicopathological features that influence how it behaves and how it is treated. This study looked at progesterone receptor (PR) expression in breast cancer cases and its associations with sociodemographic and clinicopathological factors in the state of Bayelsa. Examining a total of 75 female breast cancer patients, we considered age, histologic type, cancer stage, and tumour grade. The  mean age of  diagnosis is 45 years. The most frequent histological type, according to general trends, was invasive ductal carcinoma (72%). Although the PR expression was generally more positive in older patients, there was no statistically significant difference. Invasive lobular tumours showed a higher PR positive rate. Earlier studies on this subtype of cancer patients' features have been confirmed. Although there were differences in the percentage of PR positive patients depending on the stage of the disease, no statistically significant associations between PR expression and cancer stages were discovered. Tumours with moderate differentiation tended to express more PR, according to analysis of tumour grade. Notably, there was found to be a statistically significant link between the existence of a BRCA1 mutation and PR expression (p 0.001), suggesting that there may be a connection between BRCA1 mutations and PR expression in breast cancer. The results of this analysis help us understand the characteristics of breast cancer in the studied population. By studying the relationship between PR expression and demographic and clinicopathological traits, we provide a full understanding of PR's role in breast cancer. These results show the usefulness of using a range of factors to comprehend breast cancer behaviour and guide tailored treatment approaches. To validate these associations and enhance the therapy of breast cancer, more extensive studies are needed.

Keywords: Breast cancer, BRCA 1, progestrone, tumor grade, histologic subtypes


How to Cite

Eric E. U., & Abraham K. D. (2023). Immunohistochemical Expression Pattern of Brac 1 and Progesterone Receptors among Female Breast Cancer Patient in Bayelsa State. Asian Journal of Medical Principles and Clinical Practice, 6(2), 284–291. Retrieved from https://journalajmpcp.com/index.php/AJMPCP/article/view/189

Downloads

Download data is not yet available.

References

Kuchenbaecker C, Arnold M, Karim-Kos HE, Coebergh JW, Byrnes G, Antilla A, Ferlay J, Soerjomataram I. Recent trends in incidence of five common cancers in 26 European countries since 1988: Analysis of the European Cancer Observatory. European Journal of Cancer. 2017; 51(9):1164-1187.

Bado G, Seshie B, Adu-Aryee NA, Dedey F, Calys-Tagoe B, Clegg-Lamptey JNA. Retrospective analysis of breast cancer subtype based on ER/PR and HER2 status in Ghanaian patients at the Korle Bu Teaching Hospital, Ghana. BMC clinical pathology. 2017;15(1):14.

Parkin S, Tisserand P, Fouquet C, Barrois M, Gallou C, Dendale R, Stoppa-Lyonnet D, Soussi T. Lack of HIN-1 methylation defines specific breast tumor subtypes including medullary carcinoma of the breast and BRCA1-linked tumors. Cancer Biology & Therapy. 2011;2(5):559-563.

Forbes R, Costa VL, Henrique R, Ribeiro FR, Pinto M, Oliveira J, Lobo F, Jerónimo C. Quantitative promoter methylation analysis of multiple cancer-related genes in renal cell tumors. BMC Cancer. 2019;7(1):133.

Anderson A, Bertolo C, Guerrero D, Vicente F, Cordoba A, Esteller M, Ropero S, Lera JM. Differences and molecular immunohistochemical parameters in the subtypes of infiltrating ductal breast cancer. American; 2014.

Joshi C, Dobrolecki LE, Airhart SD, Alferez DG, Aparicio S, Behbod F, Bentires-Alj M, Brisken C, Bult CJ, Cai S, Clarke RB, et al. Patient-derived xenograft (PDX) models in basic and translational breast cancer research. Cancer Metastasis Reviews. 2016;35:547–573.

Liu D. Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke MF, Kawamura MJ & Wicha MS. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes and Development. 2011;17:1253–1270.

Bancroft JD, Gamble M. Theory and Practice of Histological Techniques. 6th Edition, Churchill Livingstone, Elsevier, China; 2008.

Eruvwahwe EF, Eric EU, Alaba OGE, MB. Deele immunohistochemical characteri-zation of genes expressed in leiomyoma using Ki67 and P53 in Patient Attending Niger Delta University Teaching Hospital. Journal of Cancer and Tumor International. 2021;11(3):30-38. Article no.JCTI.66368 ISSN: 2454-7360.

Uzoigwe O, Akarolo-Anthony SN, Ogundiran TO, Adebamowo CA. Emerging breast cancer epidemic: evidence from Africa. Breast cancer research. 2020;12(4):S8.

Veronesi D, Olopade OI, Fackenthal JD, Dunston G, Tainsky MA, Collins F, Whitfield‐Broome C. Breast cancer genetics in African Americans. Nigerian journal of clinical practice. 2015;18(4):553-558.

Ntekin A, Imam BA, Okechi OO, Abdullahi K, Abubakar U, Musa AB, Okorie N, Ibrahim KK. Immunohistochemical pattern of breast cancer in Maiduguri, Borno state. Journal of Cancer and Tumor International. 2009:1-10.

Usman Asma’u, Yawale Iliyasu, Akinfenwa Taoheed Atanda. Molecular subtyping of carcinoma of the female breast in a tertiary teaching hospital in Northern Nigeria. Annals of Tropical Pathology. 2019;10(1):20-26.

Margolin S, Werutsky G, Nunes V, Martins M, Ferrigno A, Valle E, Canelhas A. Clinicopathological features and prognosis of BRCA1 and BRCA2-mutated breast cancer in Latin America. Breast Cancer Research and Treatment. 2020;181(1):151-161.

Van der Merwe NC, van Rensburg EJ. Hereditary Breast/ovarian Cancer and BRCA Mutations: A South African Perspective. Curr. Oncol. 2009;16: 91.

Roy R, Chun J, Powell S. BRCA1 and BRCA2: Different roles in a common pathway of genome protection. Nat Rev Cancer. 2012;12:68–78. Available:https://doi.org/10.1038/nrc3181

Roy M, Mylavarapu S, Das A. Role of BRCA Mutations in the Modulation of Response to Platinum Therapy. Front. Oncol. 2018;8:16. DOI:10.3389/fonc.2018.00016

Nelson DR. Cytochrome P450 diversity in the tree of life. Biochim. Biophys. Acta Proteins Proteom 2018;1866:141–154. [CrossRef]

Umut Varol , Yuksel Kucukzeybek , Ahmet Alacacioglu , Isil Somali , Zekiye Altun , Safiye Aktas, Mustafa Oktay Tarhan BRCA 1 and BRCA 2 BRCA genes Nature. 2018;477:179–184.11